A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Evaluation of efficacy in KRAS mutated NSCLC
Journal article published in 2021 by
Matthew G. Krebs,
Rajiv Shinde,
Rozana Abdul Rahman,
Rafael Grochot,
Martin Little,
Jenny King,
Joseph Kitchin,
Mona Parmar,
Alison Turner,
Muneeb Mahmud,
Christina Yap 
,
Nina Tunariu,
Juanita Lopez,
Johann S. De Bono,
Udai Banerji
and other authors.
,
Nina Tunariu,
Juanita Lopez,
Johann S. De Bono,
Udai Banerji
and other authors.
